Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMJGleeson Regulatory News (GLE)

Share Price Information for MJGleeson (GLE)

Share Price is delayed by 15 minutes
Get Live Data
245.00    0.00 (0.00%)
Bid:
245.00
Ask:
250.00
Spread: 5.00 (2.041%)
Market Cap: £142.92m
GLE Live PriceLast checked at - London Stock Exchange

Intraday MJGleeson Share Chart

Trading Update

1 May 2026 07:00

RNS Number : 6971C
MJ Gleeson PLC
01 May 2026
 

 

MJ Gleeson plc 

("MJ Gleeson" or the "Group") 

 

Trading Update

MJ Gleeson plc is providing a trading update covering the 11 weeks to 24 April 2026 ("the Period").

 

Gleeson Homes

 

Trading

 

Gleeson Homes has experienced resilient trading through the period since 11 February, when the Group announced its H1 results. Net reservation rates for the 11 weeks to 24 April were 0.88 per site per week (0.59 excluding bulk reservations) compared to 0.86 per site per week (0.64 excluding bulk reservations) during the same period last year.

 

There has been modest build cost inflation since the start of the calendar year whilst underlying selling prices on open-market and partnership sales have been broadly stable. Protecting margin continues to be a priority.

 

Restructuring & legacy site cost provisions

 

Following the successful implementation of Project Transform, we continue to seek opportunities to improve the business, sharpening efficiency, mitigating overhead costs and focusing our investment into those regions and locations where we see optimal prospects for controlled growth.

 

From 1 July, the Yorkshire East region will be integrated into Yorkshire South and West. The creation of one Yorkshire region, and reallocation of certain sites into the Midlands region, will improve the efficiency of those regions, refocus our investment into higher return land opportunities and generate annualised regional overhead savings of £0.9m. The related costs are estimated at up to £3.1 million, comprising cash restructure costs of £0.3m and the non-cash impairment of certain conditionally purchased land assets of between £1.5m and £2.8m, and will be recognised as an exceptional item in the full-year accounts.

 

Our new management teams have identified issues on previously completed legacy developments, mainly in Yorkshire, which require rectification in order to achieve adoption of the roads (and other statutory services) by the relevant Local Authorities. As we work through these issues we expect to establish cost provisions in the current financial year estimated at between £5.2 million and £7.1 million, for remedial works to be undertaken over the next three to four years. It is expected that Adjusted results1 for the current financial year will exclude these legacy site provisions.

 

Gleeson Land

 

Gleeson Land continues to progress the sale of five sites including one site which represents approximately 50% of total plots forecast to be sold during the year. In respect of that project, we have made good progress on the required technical solution, which has now been accepted by the highways authority. The timing of conclusion of the sale is subject to formal technical approval. We will provide an update when we are clearer on that timing.

FY2026 outturn

 

With greater visibility across Gleeson Homes' Spring selling season and subject to Gleeson Land completing its major land sale, the Board expects that Adjusted Group Profit before Tax1 for the year ending 30 June 2026 will be in line with market consensus2.

 

Graham Prothero, CEO, commented:

 

"We are pleased that Gleeson Homes' trading performance has been resilient in an uncertain market environment.

 

"Whilst it is frustrating that further work is required on a number of legacy sites, I am pleased with the determination of our new management teams to identify and rectify legacy issues which now allows Gleeson Homes to look forward with confidence.

 

"It is too early to forecast the degree to which the crisis in the Middle East will impact customer confidence, mortgage affordability and build cost inflation over the coming months. We have recently seen some softening in footfall and reservations, and limited increases in the cost of some materials. This, together with ongoing challenges with planning and site viability, prompts even higher than usual caution in how we manage the business, including land investment decisions, into the next financial year.

 

"However, following the successful implementation of Project Transform, which has driven a greater focus on operational effectiveness and efficiency, the business as a whole is now in a much stronger position to manage through this period of uncertainty and capitalise on the significant opportunities we see ahead when the market returns to growth."

 

Graham Prothero, CEO, and Stefan Allanson, CFO, will host a conference call at 08:00 this morning. Institutional investors and analysts can register at mjgleeson@stoneway.co their interest in joining the call.

 

1 Adjusted Operating Profit and Adjusted Group Profit Before Tax will be determined in accordance with the Group's accounting policies and, while the classification of these costs remain under review, Adjusted Operating Profit and Adjusted Group Profit Before Tax are currently expected to exclude exceptional items and the additional completed site cost provisions which, in total, amount to between £7.0m and £10.2m. These adjustments are in addition to £0.3m exceptional items recognised in the interim results and the estimated £4.5m exceptional costs of restructuring the Greater Manchester Merseyside region announced in February 2026.

2 The company compiled consensus of Group Profit Before Tax and Exceptional items for the year ending 30 June 2026 is £18.2m with a range of £12.9m to £20.5m and can be found at: https://www.mjgleesonplc.com/investors/analyst-coverage/

 

Enquiries:

 

MJ Gleeson plc +44 1142 612 900

Graham Prothero, Chief Executive Officer

Stefan Allanson, Chief Financial Officer

 

Stoneway (Financial PR) mjgleeson@stoneway.co

Mark Garraway +44 7771 860938

Kim Looringh-van Beeck +44 20 3422 0208

 

Singer Capital Markets (Joint broker) +44 20 7496 3000

Shaun Dobson

Charles Leigh-Pemberton

 

Peel Hunt (Joint broker) +44 20 7418 8900

Ed Allsopp

Tom Graham

 

 

The information contained within this announcement was previously deemed by the Company to constitute inside information as stipulated by Market Abuse Regulation (EU) No 596/2014 ("EU MAR") and the retained UK law version of EU MAR pursuant to the Market Abuse (Amendment) (EU Exit) Regulations 2019 (SI 2019/310) ("UK MAR"). With the publication of this announcement via a Regulatory Information Service, this information is now considered to be in the public domain. For the purposes of UK MAR, the person responsible for arranging for the release of this information on behalf of MJ Gleeson plc is Stefan Allanson, Chief Financial Officer

LEI: 21380064K7N2W7FD6434

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTWPUBPCUPQPPU
Date   Source Headline
25th Mar 20204:35 pmRNSPrice Monitoring Extension
25th Mar 20203:38 pmRNSCovid-19 Update
23rd Mar 20204:40 pmRNSSecond Price Monitoring Extn
23rd Mar 20204:36 pmRNSPrice Monitoring Extension
13th Mar 202012:08 pmRNSSecond Price Monitoring Extn
13th Mar 202012:02 pmRNSPrice Monitoring Extension
9th Mar 20209:49 amRNSDirector/PDMR Shareholding
28th Feb 20207:00 amRNSTotal Voting Rights
13th Feb 202012:02 pmRNSPrice Monitoring Extension
13th Feb 20207:00 amRNSHalf-year Report
10th Feb 20202:32 pmRNSDirector/PDMR Shareholding
31st Jan 20207:00 amRNSTotal Voting Rights
9th Jan 20207:00 amRNSNotice of Results and Trading Update
8th Jan 20206:05 pmRNSDirector/PDMR Shareholding
31st Dec 20197:00 amRNSTotal Voting Rights
20th Dec 20196:09 pmRNSExercise of options, PDMR Dealing and TVR
19th Dec 201912:07 pmRNSSecond Price Monitoring Extn
19th Dec 201912:02 pmRNSPrice Monitoring Extension
18th Dec 201910:15 amRNSDirector/PDMR Shareholding
11th Dec 20195:22 pmRNSPerformance Share Plan award to Directors/PDMRs
9th Dec 201911:31 amRNSDirector/PDMR Shareholding
5th Dec 20193:18 pmRNSResult of AGM
5th Dec 20197:00 amRNSAGM Statement
3rd Dec 20194:07 pmRNSTotal Voting Rights
2nd Dec 20197:01 amRNSIncentive Plan Share Issue
2nd Dec 20197:00 amRNSAppointment of Chief Executive Officer
29th Nov 20197:00 amRNSTotal Voting Rights
12th Nov 20193:40 pmRNSPerformance Share Plan award to Directors/PDMRs
11th Nov 201910:12 amRNSDirector/PDMR Shareholding
4th Nov 20197:00 amRNSNotice of AGM
31st Oct 201912:13 pmRNSRe Committee Appointments
31st Oct 20197:00 amRNSTotal Voting Rights
16th Oct 20193:58 pmRNSHolding(s) in Company
9th Oct 201912:05 pmRNSDirector/PDMR Shareholding
9th Oct 201911:46 amRNSDirector/PDMR Shareholding
8th Oct 20192:09 pmRNSExercise of Options and Total Voting Rights
30th Sep 20197:00 amRNSTotal Voting Rights
24th Sep 20197:00 amRNSAppointment of Non-Executive Directors
24th Sep 20197:00 amRNSDirector/PDMR Shareholding
16th Sep 20197:00 amRNSFinal Results
10th Sep 20195:35 pmRNSDirector/PDMR Shareholding
30th Aug 20197:00 amRNSTotal Voting Rights
14th Aug 20194:35 pmRNSPrice Monitoring Extension
8th Aug 20199:32 amRNSDirector/PDMR Shareholding
7th Aug 20191:40 pmRNSHolding(s) in Company
31st Jul 20197:00 amRNSTotal Voting Rights
11th Jul 201910:55 amRNSDirector/PDMR Shareholding
4th Jul 20197:00 amRNSTrading Update
28th Jun 20197:00 amRNSTotal Voting Rights
10th Jun 20192:16 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.